Bengaluru, May 30 (UNI) Apollo Hospitals Enterprise Ltd on Friday announced its financial results for the fourth quarter and full financial year ended March 31, 2025, reporting a robust performance marked by record revenue and profit growth, significant expansions in key markets, and continued leadership in high-acuity care.
For FY25, Apollo’s consolidated revenue rose 14 per cent year-on-year (YoY) to ₹21,794 crore, crossing the ₹20,000 crore milestone for the first time. Healthcare Services contributed ₹11,147 crore, up 13 per cent YoY. The group reported a 26 per cent surge in EBITDA at ₹3,022 crore, while net profit (PAT) jumped 61 per cent to ₹1,446 crore.
During Q4 FY25, consolidated revenue grew 13 per cent YoY to ₹5,592 crore. EBITDA increased by 20 per cent YoY to ₹770 crore, and net profit soared 54 per cent to ₹390 crore. Diluted earnings per share stood at ₹27.10 for the quarter.
The Board recommended a final dividend of ₹10 per share, taking the total dividend to ₹19 per share on a face value of ₹5 each for FY25.
In a major development, Apollo Hospitals announced a significant expansion in Bengaluru’s Sarjapur micro-market. The two-stage project includes the acquisition of a 200-bed leased facility and a new 500-bed greenfield hospital. Alongside existing brownfield expansions, this will raise Apollo’s total bed capacity in Bengaluru to approximately 1,500.
Similarly, in Hyderabad, a 160-bed brownfield expansion is underway at Jubilee Hills and Secunderabad. Including the upcoming Gachibowli unit, the city will have a total Apollo bed strength of around 1,400.
The hospital group aims to add over 4,300 beds over the next 3–4 years with a capital outlay exceeding ₹8,000 crore, of which more than ₹6,000 crore remains to be invested.
Apollo also achieved a landmark 25,000 transplants across its network, further reinforcing its position as a leader in complex, high-acuity care.
Chairman Dr Prathap C Reddy said, “FY25 was a defining year. With revenues crossing ₹20,000 crore and Healthcare Services surpassing ₹11,000 crore, we are humbled by the trust placed in us across India and beyond. As we grow, our focus remains unwavering—making advanced, high-quality care accessible and affordable to all.”
He noted the company’s growing emphasis on preventive healthcare through the Apollo ProHealth platform, and its commitment to innovation, including AI-driven diagnostics and robotic surgeries.
Segment-wise, Apollo HealthCo recorded revenues of ₹9,093 crore in FY25 (up 16 pc YoY), while AHLL (Apollo Health and Lifestyle Ltd) posted revenues of ₹1,554 crore, up 14 pc. Apollo 24|7 achieved a GMV of ₹3,007 crore during the year.
Healthcare Services alone reported a 25 per cent YoY increase in PAT to ₹1,426 crore, with an EBITDA of ₹2,701 crore (up 15 pc). AHLL, despite narrowing losses, reported a PAT loss of ₹27 crore. Apollo HealthCo turned profitable with a PAT of ₹47 crore, reversing a loss of ₹195.7 crore in FY24.
As of March 31, 2025, Apollo operated 8,025 hospital beds (excluding AHLL and managed beds), with an overall occupancy rate of 67 per cent. Notable regional performances included 19 per cent revenue growth in the AP-Telangana cluster and 15 per cent growth in Karnataka.
Apollo Pharmacies, operated by Apollo HealthCo, reached 6,626 stores nationwide, with 266 net new additions in Q4. The digital platform, Apollo 24/7, achieved an average order run rate of 83,000 per day in the quarter.
Dr Reddy highlighted Apollo’s ongoing investments in new hospitals in Pune, Kolkata, Hyderabad, Bengaluru, and Delhi NCR, reinforcing its commitment to scaling world-class care across India.
“As we step into FY26, our purpose remains clear: to touch a billion lives, lead with innovation and empathy, and help build a healthier, stronger India for future generations,” he said.
UNI BDN GNK